<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03500380</url>
  </required_header>
  <id_info>
    <org_study_id>RC48-C006</org_study_id>
    <nct_id>NCT03500380</nct_id>
  </id_info>
  <brief_title>A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases</brief_title>
  <official_title>A Randomized, Controlled, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Breast Cancer and Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Advanced Breast With Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open, parallel-controlled, multicenter, phase II/III, seamless design&#xD;
      clinical trial to compare the efficacy and safety of RC48-ADC with capecitabine + lapatinib&#xD;
      in locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) positive&#xD;
      breast cancer and HER2-positive advanced breast cancer with liver metastasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by an IRC</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Tumor response was assessed by an IRC according to RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by Investigator</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Tumor response was assessed by investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate （ORR）</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DOR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate （CBR）</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments &gt;/=4 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 48 months</time_frame>
    <description>OS was defined as the time from the date of randomization to the date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">301</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Diseases</condition>
  <condition>Capecitabine</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>HER2 Positive Breast Carcinoma</condition>
  <condition>HER2-positive Advanced Breast With Liver Metastases</condition>
  <arm_group>
    <arm_group_label>RC48-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RC48-ADC 2.0 mg/kg intravenous (IV) infusion each 14-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lapatinib + Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive lapatinib 1250 mg orally once daily during each 21-day cycle + capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48-ADC</intervention_name>
    <description>RC48-ADC 2.0 mg/kg IV every 14 days</description>
    <arm_group_label>RC48-ADC</arm_group_label>
    <other_name>RC48</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Lapatinib 1250 mg orally once daily during each 21-day cycle.</description>
    <arm_group_label>Lapatinib + Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle.</description>
    <arm_group_label>Lapatinib + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for the first phase randomized control period:&#xD;
&#xD;
          -  Voluntarily agree to participate in the study and sign the informed consent form.&#xD;
&#xD;
          -  Subjects aged 18 - 70 years (inclusive), and the subject who have not reached the age&#xD;
             of 71 years old will be considered to be ≤ 70 years of age.&#xD;
&#xD;
          -  Expected survival ≥ 12 weeks.&#xD;
&#xD;
          -  ECOG PS score 0 or 1.&#xD;
&#xD;
          -  Female subjects should be surgically sterilized or in post-menopausal status, or agree&#xD;
             to use at least one medically accepted contraceptive methods (such as intrauterine&#xD;
             device, contraceptive drug or condom) during study treatment period and for up to 6&#xD;
             months after the study treatment is completed, and the blood pregnancy test must be&#xD;
             negative within 7 days prior to study enrollment, and they must not be lactating. For&#xD;
             male subjects: all the subjects should be surgically sterilized or agree to use one of&#xD;
             the medically approved contraceptive methods during the study treatment period and for&#xD;
             an additional of 6 months after the end of the study treatment period.&#xD;
&#xD;
          -  Able to understand study requirements, willing and able to comply with study protocol&#xD;
             and follow-up procedures.&#xD;
&#xD;
        With Adequate Organ Function&#xD;
&#xD;
          -  Bone marrow function:&#xD;
&#xD;
        Hemoglobin ≥ 9 g/dL; Absolute neutrophil count ≥ 1.5×109/L; Platelets ≥ 100 × 109/L;&#xD;
&#xD;
          -  Liver function (based on the normal values specified by study site):&#xD;
&#xD;
        Serum total bilirubin ≤ 1.5 × the upper limit of normal (ULN); Alanine aminotransferase&#xD;
        (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ 2.5 × ULN in the&#xD;
        absence of liver metastases, while ALT, AST and ALP ≤ 5 × ULN in the presence of liver&#xD;
        metastases;&#xD;
&#xD;
          -  Renal function (based on the normal values specified by study site):&#xD;
&#xD;
        Serum creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) ≥ 60 mL/min as calculated by&#xD;
        Cockcroft-Gault formula, or 24-hour urine Crcl ≥ 60 mL/min;&#xD;
&#xD;
          -  Cardiac function:&#xD;
&#xD;
        New York Heart Association (NYHA) classification &lt; Grade III; Left ventricular ejection&#xD;
        fraction ≥ 50%; Tumor Related Criteria&#xD;
&#xD;
          -  Histologically and/or cytologically confirmed invasive locally advanced or metastatic&#xD;
             breast cancer that is incurable and unresectable;&#xD;
&#xD;
          -  Positive HER2 expression (positive defined as: IHC 3+ or FISH+); previous test results&#xD;
             of HER2 expression provided by the subjects (have to be confirmed by the investigator)&#xD;
             and those obtained from the study site or the central laboratory were both acceptable;&#xD;
             subject are able to provide samples from primary or metastatic tumor sites for HER2&#xD;
             test (either paraffin blocks, paraffin-embedded sections, or sections prepared using&#xD;
             freshly excised tissues);&#xD;
&#xD;
          -  With prior taxane therapy (monotherapy or in combination with other drugs, treatment&#xD;
             duration should be ≥ 2 cycles);&#xD;
&#xD;
          -  With prior adjuvant therapy, have received treatment with trastuzumab or its&#xD;
             biosimilar for patients with locally advanced cancer or metastasis during relapse and&#xD;
             metastasis (monotherapy or in combination with other drugs, such as for ≥ 3 months in&#xD;
             the adjuvant therapy phase, and ≥ 6 weeks in the post-relapse and metastatic phase);&#xD;
&#xD;
          -  With evidence of tumor progression during or after the most recent treatment as&#xD;
             confirmed by the investigator or with documented history;&#xD;
&#xD;
          -  No more than 2 lines of chemotherapy received after relapse/metastasis. The number of&#xD;
             chemotherapy lines is restricted to chemotherapeutic drugs, and each chemotherapy&#xD;
             regimen is counted as a number of chemotherapy line, excluding targeted drugs and/or&#xD;
             endocrine drugs; the same maintenance treatment as the previous chemotherapy regimen&#xD;
             will not be counted.&#xD;
&#xD;
          -  With at least one measurable lesion per RECIST v1.1.&#xD;
&#xD;
        Exclusion Criteria for Randomized Controlled Period in Stage I:&#xD;
&#xD;
          -  Use of investigational drugs within 4 weeks prior to study treatment;&#xD;
&#xD;
          -  Have received major surgeries within 4 weeks prior to study treatment and have not&#xD;
             recovered yet;&#xD;
&#xD;
          -  Have received a live vaccine inoculation within 4 weeks prior to the start of study&#xD;
             drug administration or was scheduled to receive any vaccine during the study;&#xD;
&#xD;
          -  Have experienced arterial/venous thromboembolic events, such as cerebrovascular&#xD;
             accident (including transient ischemic attack), deep vein thrombosis and pulmonary&#xD;
             embolism within 1 year prior to the initiation of study treatment;&#xD;
&#xD;
          -  Suffering uncontrolled systemic diseases, including diabetes, hypertension, pulmonary&#xD;
             fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc.;&#xD;
&#xD;
          -  Currently suffering from active infections requiring systemic treatment;&#xD;
&#xD;
          -  With history of active tuberculosis;&#xD;
&#xD;
          -  With positive HIV test result;&#xD;
&#xD;
          -  Patients with active hepatitis B or C (HBsAg positive and HBV DNA positive; HCVAb&#xD;
             positive);&#xD;
&#xD;
          -  Presence of effusion in the third space (including massive hydrothorax or ascites)&#xD;
             that cannot be controlled by drainage or other methods;&#xD;
&#xD;
          -  With known hypersensitivity or delayed-type hypersensitivity to certain components of&#xD;
             RC48-ADC, capecitabine, lapatinib or similar drugs;&#xD;
&#xD;
          -  With pre-existing gastrointestinal disorders that may affect absorption, such as&#xD;
             ileus, ulcerative colitis, chronic diarrhea, inability to swallow, and other&#xD;
             conditions that may affect drug administration and absorption;&#xD;
&#xD;
          -  With known psychiatric disorders or drug abuse disorders that might have an impact on&#xD;
             compliance with protocol requirements;&#xD;
&#xD;
          -  Have any other diseases, metabolic disorders, abnormal physical examination findings&#xD;
             or abnormal laboratory test results, which, judged by the investigator, are reasonably&#xD;
             to suspect a disease or condition as a contraindication of the study drug, or may&#xD;
             interfere the interpretation of the study results in the future, or that put the&#xD;
             patient at a high risk;&#xD;
&#xD;
          -  Women who are pregnant or during lactation period or women/men with childbearing&#xD;
             plans;&#xD;
&#xD;
          -  Subjects who are estimated to have poor compliance with the clinical study or the&#xD;
             investigator determines that there are other factors not appropriate to participate in&#xD;
             the study;&#xD;
&#xD;
          -  Presence of brain metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Had any other malignancy within 5 years prior to signing of the informed consent&#xD;
             (except for non-melanoma skin cancer, cervix carcinoma in situ or other tumor that&#xD;
             have been effectively treated and considered to be cured);&#xD;
&#xD;
          -  Have received prior chemotherapy, radiotherapy, immunotherapy within 4 weeks prior to&#xD;
             the first dose of the study drug;&#xD;
&#xD;
          -  Have received hormonal therapy for breast cancer within 2 weeks prior to the start of&#xD;
             study treatment;&#xD;
&#xD;
          -  Patients who received palliative radiotherapy for bone metastases within 2 weeks&#xD;
             before the start of study treatment;&#xD;
&#xD;
          -  Have received anti-tumor traditional Chinese medicine within 2 weeks prior to the&#xD;
             start of study treatment;&#xD;
&#xD;
          -  Have received capecitabine within 6 months prior to the start of study treatment, or&#xD;
             have failed to respond to prior treatment with capecitabine (including progression&#xD;
             while on capecitabine treatment or maintenance of clinical efficacy for a period of&#xD;
             less than 6 months after treatment), or with intolerance to capecitabine. Patients who&#xD;
             have received capecitabine as adjuvant therapy and have discontinued this therapy for&#xD;
             ≥ 6 months are eligible;&#xD;
&#xD;
          -  The toxicity of prior anti-tumor therapy had not recovered to CTCAE [Version 4.03]&#xD;
             Grade 0-1, with the following exceptions: a). alopecia; b). pigmentation; c).&#xD;
             long-term toxicity caused by radiotherapy, which are considered as irreversible by the&#xD;
             investigator;&#xD;
&#xD;
          -  With prior systemic therapy with or participation in clinical studies with HER2&#xD;
             tyrosine kinase inhibitors (TKIs);&#xD;
&#xD;
          -  With prior treatment with T-DM1 or had participated in clinical studies with same&#xD;
             class of drugs.&#xD;
&#xD;
          -  With known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase&#xD;
             deficiency.&#xD;
&#xD;
        Inclusion Criteria for Stage 1 Cross-over Period：&#xD;
&#xD;
          -  Had previously participated in the study of randomized controlled period and received&#xD;
             lapatinib plus capecitabine, and received no anti-tumor treatment after disease&#xD;
             progression (RECIST v1.1 criteria);&#xD;
&#xD;
          -  The general situation part refers to the selection criteria of the first stage&#xD;
             randomized control period.&#xD;
&#xD;
        Exclusion Criteria for Cross-over Period in Stage I：&#xD;
&#xD;
          -  Have received major surgeries within 4 weeks prior to study treatment and have not&#xD;
             recovered yet;&#xD;
&#xD;
          -  Have received a live vaccine inoculation within 4 weeks prior to the start of study&#xD;
             drug administration or was scheduled to receive any vaccine during the study (except&#xD;
             the COVID-19 vaccine);&#xD;
&#xD;
          -  Have experienced arterial/venous thromboembolic events, such as cerebrovascular&#xD;
             accident (including transient ischemic attack), deep vein thrombosis and pulmonary&#xD;
             embolism within 1 year prior to the initiation of study treatment;&#xD;
&#xD;
          -  Suffering uncontrolled systemic diseases, including diabetes, hypertension, pulmonary&#xD;
             fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc.;&#xD;
&#xD;
          -  Currently suffering from active infections requiring systemic treatment;&#xD;
&#xD;
          -  With positive HIV test result;&#xD;
&#xD;
          -  Patients with active hepatitis B or C (HBsAg positive and HBV DNA positive; HCVAb&#xD;
             positive);&#xD;
&#xD;
          -  Presence of effusiona in the third space (including massive hydrothorax or ascites)&#xD;
             that cannot be controlled by drainage or other means;&#xD;
&#xD;
          -  With known hypersensitivity or delayed-type hypersensitivity to certain components of&#xD;
             RC48-ADC or similar drugs;&#xD;
&#xD;
          -  With known psychiatric disorders or drug abuse disorders that might have an impact on&#xD;
             compliance with protocol requirements;&#xD;
&#xD;
          -  Have any other diseases, metabolic disorders, abnormal physical examination findings&#xD;
             or abnormal laboratory test results, which, judged by the investigator, are reasonably&#xD;
             to suspect a disease or condition as a contraindication of the study drug, or may&#xD;
             interfere the interpretation of the study results in the future, or that put the&#xD;
             patient at a high risk;&#xD;
&#xD;
          -  Women who are pregnant or in lactation period or women/men with childbearing plans;&#xD;
&#xD;
          -  Subjects who are estimated to have poor compliance with the protocol of this&#xD;
             cross-over period or the investigator determines that there are other factors not&#xD;
             appropriate to participate in the study;&#xD;
&#xD;
          -  Presence of brain metastases and/or carcinomatous meningitis. Have received prior&#xD;
             treatment for brain metastases may be considered for participating in this study,&#xD;
             provided that the diseases were stable, had no disease progression as confirmed by&#xD;
             imaging examinations within 4 weeks prior to the first dose of the investigational&#xD;
             product (IP), and that all neurological symptoms have recovered to baseline level&#xD;
             without any evidence of newly emerging or spread brain metastases; moreover, treatment&#xD;
             with radiation, surgery or steroids was discontinued at least 14 days prior to the&#xD;
             first dose of study drug. This exception did not include cancerous meningitis, which&#xD;
             should be excluded regardless of the stability of its clinical status;&#xD;
&#xD;
          -  Patients who received palliative radiotherapy for bone metastases within 2 weeks&#xD;
             before the start of study treatment;&#xD;
&#xD;
          -  Received treatment with lapatinib and/or capecitabine within 2 weeks prior to the&#xD;
             first dose of the study drug;&#xD;
&#xD;
          -  The toxicity of prior anti-tumor therapy had not recovered to CTCAE [Version 4.03]&#xD;
             Grade 0-1, with the following exceptions: a). alopecia; b). pigmentation; c).&#xD;
             long-term toxicity caused by radiotherapy, which are considered as irreversible by the&#xD;
             investigator;&#xD;
&#xD;
        Inclusion Criteria for Randomized Controlled Period in Stage II：&#xD;
&#xD;
          -  The general situation part refers to the selection criteria of the first stage&#xD;
             randomized control period.&#xD;
&#xD;
        Exclusion Criteria for Randomized Controlled Period in Stage II：&#xD;
&#xD;
          -  The toxicity of prior anti-tumor therapy had not recovered to CTCAE [Version 5.0]&#xD;
             Grade 0-1, with the following exceptions: a). alopecia; b). pigmentation; c).&#xD;
             long-term toxicity caused by radiotherapy, which are considered as irreversible by the&#xD;
             investigator;&#xD;
&#xD;
          -  The remaining parts refer to the exclusion criteria of the first stage randomized&#xD;
             control period.&#xD;
&#xD;
        Inclusion Criteria for Cross-over Period in Stage II：&#xD;
&#xD;
          -  Had previously participated in the study of randomized controlled period and received&#xD;
             lapatinib plus capecitabine, and received no anti-tumor treatment after disease&#xD;
             progression (RECIST v1.1 criteria);&#xD;
&#xD;
          -  Expected survival ≥ 12 weeks;&#xD;
&#xD;
          -  ECOG PS score 0 or 1;&#xD;
&#xD;
          -  Female subjects should be surgically sterilized or in post-menopausal status, or agree&#xD;
             to use at least one medically accepted contraceptive methods (such as intrauterine&#xD;
             device, contraceptive drug or condom) during study treatment period and for up to 6&#xD;
             months after the study treatment is completed, and the blood pregnancy test must be&#xD;
             negative within 7 days prior to study enrollment, and they must not be lactating. For&#xD;
             male subjects: all the subjects should be surgically sterilized or agree to use one of&#xD;
             the medically approved contraceptive methods during the study treatment period and for&#xD;
             an additional of 6 months after the end of the study treatment period.&#xD;
&#xD;
          -  Able to understand study requirements, willing and able to comply with study protocol&#xD;
             and follow-up procedures.&#xD;
&#xD;
        With Adequate Organ Function&#xD;
&#xD;
          -  Bone marrow function:&#xD;
&#xD;
        Hemoglobin ≥ 9 g/dL; Absolute neutrophil count ≥ 1.5×109/L; Platelets ≥ 100 × 109/L;&#xD;
&#xD;
          -  Liver function (based on the normal values specified by study site):&#xD;
&#xD;
        Serum total bilirubin ≤ 1.5 × the upper limit of normal (ULN); Alanine aminotransferase&#xD;
        (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ 2.5 × ULN in the&#xD;
        absence of liver metastases, while ALT, AST and ALP ≤ 5 × ULN in the presence of liver&#xD;
        metastases;&#xD;
&#xD;
          -  Renal function (based on the normal values specified by study site):&#xD;
&#xD;
        Serum creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) ≥ 60 mL/min as calculated by&#xD;
        Cockcroft-Gault formula, or 24-hour urine Crcl ≥ 60 mL/min;&#xD;
&#xD;
          -  Cardiac function:&#xD;
&#xD;
        New York Heart Association (NYHA) classification &lt; Grade III; Left ventricular ejection&#xD;
        fraction ≥ 50%;&#xD;
&#xD;
        Exclusion Criteria for Cross-over Period in Stage II：&#xD;
&#xD;
          -  The toxicity of prior anti-tumor therapy had not recovered to CTCAE [Version 5.0]&#xD;
             Grade 0-1, with the following exceptions: a. alopecia; b. pigmentation; c. long-term&#xD;
             toxicity caused by radiotherapy, which are considered as irreversible by the&#xD;
             investigator;&#xD;
&#xD;
          -  The remaining parts refer to the exclusion criteria of the first phase of the&#xD;
             crossover period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Fang</last_name>
    <phone>+8610-58075763</phone>
    <email>jianminfang@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binghe Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuee teng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Fan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quchang Ouyang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiyang Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enxiang Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shouman Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heping Hospital Affiliated to Changzhi Medical College</name>
      <address>
        <city>Changzhi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengsheng Cui</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Chengde Medical University</name>
      <address>
        <city>Chengde</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingshan Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital,Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing University Three gorges Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huawen Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Southwest Hospital of AMU</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Liao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herui Yao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongsheng Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guizhou Cancer Hospital</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Ha'erbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peifen Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongchuan Deng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojia Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changlu Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Province Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueyin Pan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kangsheng Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuwen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Jining</name>
      <address>
        <city>Jining</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuangqing Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingfen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science &amp; Technology</name>
      <address>
        <city>Luoyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinshuai Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jifeng Feng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weimin Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Neijiang</name>
      <address>
        <city>Neijiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xujuan Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haibo Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Shao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianbao Zhan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunwei Shen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>De Zeng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunjiang Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Bethune Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinnan Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinzheng Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospitial</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongsheng Tong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weihai Municipal Hospital</name>
      <address>
        <city>Weihai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hairong Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinhong Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huihua Xiong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of the Fourth Military University of P.L.A.</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Ling</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinxiang Medical University</name>
      <address>
        <city>Xinxiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liuzhong Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengqiu Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yanbian University Hospital</name>
      <address>
        <city>Yanbian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Songnan Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangming Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanting Gu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 8, 2018</study_first_submitted>
  <study_first_submitted_qc>April 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

